Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM (Abemaciclib), a twice daily oral cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA). VERZENIO is used in combination with fulvestrant to treat women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer, or breast cancer that has spread to other parts of the body (metastatic), whose disease has progressed after receiving hormonal therapy. VERZENIO is also approved as a monotherapy to treat adults with HR–positive, HER2–negative advanced breast cancer, or metastatic breast cancer whose disease has progressed after receiving hormonal therapy and chemotherapy in the metastatic setting.
“VERZENIO is a highly anticipated product that provides another therapy option for patients battling advanced breast cancer,” said Onco360 President and CEO Paul Jardina. “The world’s top biopharmaceutical companies, including Eli Lilly, continue to leverage Onco360’s patient-centric approach to cancer care when choosing a pharmacy network to distribute their pioneering new treatments in oncology. We are pleased to have been selected to join the limited distribution network for VERZENIO and look forward to providing outstanding care to patients who have a critical need for this therapy.”
About Onco360 Oncology Pharmacy:
Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC, ACHC, and JCAHO-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, KY, and is a part of PharMerica Corporation (NYSE: PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360 please visit www.Onco360.com.
Robert Dries, 502-627-7140
Executive Vice President and
Chief Financial Officer